Mark W. Kunkel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mark W. Kunkel has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Beverly A. Teicher
National Cancer Institute 2 Division of Cancer Treatment and Diagnosis National Institutes of Health, Bethesda, Maryland
49 shared publications - James H. Doroshow
Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, USA
49 shared publications - Joel Morris
Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland
49 shared publications - Nathan P. Coussens
Frederick National Laboratory for Cancer Research 1 Molecular Pharmacology Laboratory, Applied and Developmental Research Directorate Frederick, Maryland
49 shared publications - Thomas S. Dexheimer
Molecular Pharmacology Laboratory, Applied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, 21702
49 shared publications - Eric M. Jones
Frederick National Laboratory for Cancer Research 1 Molecular Pharmacology Laboratory, Applied and Developmental Research Directorate Frederick, Maryland
42 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Correlation plots BET-targeting agents.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Correlation plots BET-targeting agents.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Correlation plots PI3K-targeting agents
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Correlation plots PI3K-targeting agents
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Correlation plots mTor-targeting agents.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Correlation plots mTor-targeting agents.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Table listing NCI60 cell lines, disease of origin and key genetic alterations
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Table listing NCI60 cell lines, disease of origin and key genetic alterations
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Correlation plots agents targeting BRAF, MEK or ERK.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Correlation plots agents targeting BRAF, MEK or ERK.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Aggregate correlations of compound pairs grouped by target for 91 targets with more than a single representative compound
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Aggregate correlations of compound pairs grouped by target for 91 targets with more than a single representative compound
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Diagram outlining processing of assay data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Diagram outlining processing of assay data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Supplementary Figure S3 from HTS384 NCI60: The Next Phase of the NCI60 Screen
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Supplementary Figure S3 from HTS384 NCI60: The Next Phase of the NCI60 Screen
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Representative conc/resp BET-targeting agents and NAMPRTase-targeting agents.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Representative conc/resp BET-targeting agents and NAMPRTase-targeting agents.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Diagram outlining COMPARE calculations and data presentation formats.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Diagram outlining COMPARE calculations and data presentation formats.